<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111049</article-id><article-id pub-id-type="publisher-id">ACM-40027</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_91887659.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肠道菌群与慢性肾脏病的研究进展
  Research Progress of Intestinal Flora and Chronic Kidney Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>薛</surname><given-names>雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>立红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>俊芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>洁晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>永玲</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国人民解放军联勤保障部队第九二四医院检验科，广西代谢性疾病研究重点实验室，广西 桂林</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>中国人民解放军联勤保障部队第九二四医院卫勤处，广西 桂林</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>345</fpage><lpage>349</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    慢性肾脏疾病(chronic kidney disease, CKD)近年来的发病率逐年升高，严重威胁着人类的健康和生命。其包括由各种因素引起的原发性、继发性肾脏疾病。肥胖、糖尿病、高血压、肾小球肾炎都可导致CKD，CKD已经成为全球性公共健康问题，其患病率和病死率高。本文针对肠道菌群对慢性肾脏病的影响进行综述，肠道菌群失调与CKD的发生关系密切，可为以肠道菌群为靶点的预防和治疗相关疾病提供强有力的理论基础。
    The incidence of chronic kidney disease (CKD) is increasing year by year in recent years, which threatens human health and life seriously. CKD includes primary and secondary renal diseases caused by various factors. Obesity, diabetes, high blood pressure, and glomerulonephritis can all lead to CKD, which has become a global public health problem with high morbidity and mortality. This article reviews the influence of Intestinal microflora on chronic kidney disease. The imbalance of intestinal microflora is closely related to CKD, which provides a strong theoretical basis for the prevention and treatment of diseases related to intestinal microflora. 
  
 
</p></abstract><kwd-group><kwd>肠道菌群，慢性肾脏病，菌群失调，机体疾病, Gut Flora</kwd><kwd> Chronic Kidney Disease</kwd><kwd> Dysbacteriosis</kwd><kwd> Diseases of the Body</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>慢性肾脏疾病(chronic kidney disease, CKD)近年来的发病率逐年升高，严重威胁着人类的健康和生命。其包括由各种因素引起的原发性、继发性肾脏疾病。肥胖、糖尿病、高血压、肾小球肾炎都可导致CKD，CKD已经成为全球性公共健康问题，其患病率和病死率高。本文针对肠道菌群对慢性肾脏病的影响进行综述，肠道菌群失调与CKD的发生关系密切，可为以肠道菌群为靶点的预防和治疗相关疾病提供强有力的理论基础。</p></sec><sec id="s2"><title>关键词</title><p>肠道菌群，慢性肾脏病，菌群失调，机体疾病</p></sec><sec id="s3"><title>Research Progress of Intestinal Flora and Chronic Kidney Disease<sup> </sup></title><p>Wen Xue<sup>1</sup>, Lihong Tang<sup>1</sup>, Junfang Zhu<sup>1</sup>, Jiejing Chen<sup>1</sup>, Yongling Liu<sup>2*</sup></p><p><sup>1</sup>Guangxi Key Laboratory of Metabolic Diseases Research, Department of Clinical Laboratory of Guilin No. 924 Hospital, Guilin Guangxi</p><p><sup>2</sup>Medical Department of Guilin No. 924 Hospital, Guilin Guangxi</p><p><img src="//html.hanspub.org/file/49-1571896x4_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/49-1571896x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>The incidence of chronic kidney disease (CKD) is increasing year by year in recent years, which threatens human health and life seriously. CKD includes primary and secondary renal diseases caused by various factors. Obesity, diabetes, high blood pressure, and glomerulonephritis can all lead to CKD, which has become a global public health problem with high morbidity and mortality. This article reviews the influence of Intestinal microflora on chronic kidney disease. The imbalance of intestinal microflora is closely related to CKD, which provides a strong theoretical basis for the prevention and treatment of diseases related to intestinal microflora.</p><p>Keywords:Gut Flora, Chronic Kidney Disease, Dysbacteriosis, Diseases of the Body</p><disp-formula id="hanspub.40027-formula47"><graphic xlink:href="//html.hanspub.org/file/49-1571896x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/49-1571896x8_hanspub.png" /> <img src="//html.hanspub.org/file/49-1571896x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肠道微生物是指动物肠道中存在的数量庞大的微生物群，这群微生物寄生于动物的肠道生活，并且帮助寄主完成多种生理生化功能。正常的人体内存在多种微生物群，尤其在肠道中，这些微生物群(即肠道菌群)不仅数量庞大，而且种类繁多。人体肠道为微生物提供了良好的栖息环境，成人肠道内的微生物群数量高达10~14个；重量达到1.2千克，接近人体肝脏的重量；其包含的基因数目约是人体自身的150倍 [<xref ref-type="bibr" rid="hanspub.40027-ref1">1</xref>]。作为人体最庞大、最复杂的微生态系统，这些微生物群和人体之间存在着某种“互动”，在维持正常免疫防御功能中发挥着极其重要的作用。诺贝尔生理学奖获得者Joshua Lederberg曾指出，人体与人体共生微生物构成了超级生物体(superorganism) [<xref ref-type="bibr" rid="hanspub.40027-ref2">2</xref>]。</p></sec><sec id="s6"><title>2. 肠道菌群与机体疾病</title><p>在正常情况下，肠道微生物菌群与机体内外环境维持着动态的平衡。但是当动态的平衡被打乱，就会引起生理功能、代谢功能的改变，将引起机体疾病，如：肠道、大脑、肝脏、肾脏等。临床上的疾病表现主要有炎症性肠病(inflammatory bowel disease, IBD)、慢性炎症脂代谢异常、糖尿病、过敏性疾病、心血管疾病、肿瘤、肥胖等。</p>益生菌调节肠道菌群<p>益生菌(Probiotics)是一类对宿主有益的活性微生物，是定植于人体肠道、生殖系统内，能产生对宿主有益的功效从而改善宿主的微生态平衡，并发挥对肠道有益作用的活性有益微生物的总称。主要有：乳酸菌、酪酸梭菌、双歧杆菌、放线菌、嗜酸乳杆菌、酵母菌等。正常肠道中的益生菌能促进肠黏膜上皮细胞的更新、促进淋巴样组织的成熟来维持促炎因子和抗炎因子的平衡，从而起到保护肠道的功能。目前益生菌可以制成微生态试剂，应用于生物工程、工农业、食品安全以及肠道多种疾病的治疗 [<xref ref-type="bibr" rid="hanspub.40027-ref3">3</xref>]。有研究表明，在慢性肾脏病(CKD)中，适当的补充嗜嗜热链球菌、酸乳酸菌、长双歧杆菌等益生菌，CKD患者血液中尿素水平明显降低 [<xref ref-type="bibr" rid="hanspub.40027-ref4">4</xref>]。用双歧杆菌治疗缺血/再灌注小鼠，发现血液中内毒素水平降低、促炎症因子分泌减少，SCFAs水平明显增高 [<xref ref-type="bibr" rid="hanspub.40027-ref5">5</xref>]。</p></sec><sec id="s7"><title>3. 肠道菌群与慢性肾脏病的关系</title><sec id="s7_1"><title>3.1. 慢性肾脏病</title><p>慢性肾脏疾病(chronic kidney disease, CKD)是一个全球性的医学问题，近年来CKD的发病率逐年升高，严重威胁着人类的健康和生命。慢性肾脏病(chronic kidney disease; CKD)指经肾活检或检测肾损伤标志物证实的肾脏损伤或肾小球滤过率持续&lt;60 mL/(min∙1.73m<sup>2</sup>) ≥3个月 [<xref ref-type="bibr" rid="hanspub.40027-ref6">6</xref>]，它包括由各种因素引起的原发性、继发性肾脏疾病。肥胖、糖尿病、高血压、肾小球肾炎都可导致CKD，CKD已经成为全球性公共健康问题，其患病率和病死率高。全球发病率为8%~16%，在我国的发病率约为10.8% [<xref ref-type="bibr" rid="hanspub.40027-ref7">7</xref>]。</p><p>早期发现、早期诊断能够有效地提高该病的治疗效果，从而减轻个人和社会的负担。因此，对CKD的深入研究，有助于阐明CKD发病机制，有助于早期诊断和提高疗效，也有助于寻找新药的作用靶点。引起慢性肾脏病的疾病包括各种原发的、继发的肾小球肾炎、肾小管损伤和肾血管的病变等。根据GFR可以将慢性肾脏病分为5期，早期发现和早期干预可以显著的降低CKD患者的并发症，明显的提高生存率，对于CKD的治疗，包括原发病的治疗，各种危险因素的处理以及延缓慢性肾功能不全的进展，当CKD患者进展至5期时，应及时进行肾脏替代治疗。</p></sec><sec id="s7_2"><title>3.2. CKD患者肠道菌群变化</title><p>CKD患者肠道菌群与机体内环境的动态平衡被打破，肠道菌群的数量和比例都发生了变化。研究发现尿毒症患者透析组和非透析组粪便中长双歧杆菌和嗜酸乳杆菌水平均明显降低，而大肠杆菌和粪肠球菌水平均明显升高，其中嗜酸乳杆菌水平降低及粪肠球菌水平升高均可能加重尿毒症患者的微炎性反应 [<xref ref-type="bibr" rid="hanspub.40027-ref8">8</xref>]。</p><p>透析尿毒症患者王尊松等 [<xref ref-type="bibr" rid="hanspub.40027-ref8">8</xref>] 对60例非透析尿毒症患者、60例透析尿毒症患者及30例健康志愿者的粪便进行分析，发现透析尿毒症和非透析尿毒症患者粪便中长双歧杆菌、嗜酸乳杆菌水平明显降低，粪肠球菌、大肠埃希菌水平明显升高。</p></sec><sec id="s7_3"><title>3.3. 肠道菌群对慢性肾脏病的影响</title><p>研究发现，服用长双歧杆菌可以显著降低透析前的血清同型半胱氨酸、三酰甘油和硫酸吲哚浓度，从而改善患者症状，降低尿毒症相关并发症 [<xref ref-type="bibr" rid="hanspub.40027-ref9">9</xref>]。肠道菌群参与了许多尿毒症毒素的产生，如硫酸吲哚和P-甲酚，而P-甲酚与透析患者的死亡率密切相关 [<xref ref-type="bibr" rid="hanspub.40027-ref10">10</xref>]，硫酸吲哚酚可以加速慢性肾脏病的进展 [<xref ref-type="bibr" rid="hanspub.40027-ref11">11</xref>]。大肠杆菌分解色氨酸产生吲哚，吸收入血后在肝脏合成硫酸吲哚酚，硫酸吲哚酚是促进慢性肾脏病进展的重要物质。双歧杆菌不能激活色氨酸酶，不产生吲哚，因此口服双歧杆菌可以降低血清中硫酸吲哚酚浓度，减少尿毒症毒素的产生，从而延缓慢性肾脏病进展 [<xref ref-type="bibr" rid="hanspub.40027-ref9">9</xref>]。</p><p>肠道微生物菌群在肠道内能够发酵色氨酸而产生吲哚乙酸盐和吲哚，吲哚在肝脏中代谢并产生硫酸吲哚酚(indoxyl sulfate, IS)。研究者指出，IS具有肾毒性，能够通过激活氧簇-NF-KB-p53通路加速近端小管细胞老化和CKD进程。血清IS水平可以预测CKD患者的CVD (cardiovascular diseases, C)风险 [<xref ref-type="bibr" rid="hanspub.40027-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40027-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40027-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40027-ref15">15</xref>]。</p></sec><sec id="s7_4"><title>3.4. CKD患者引起肠道菌群失调的原因</title><p>CKD患者引起肠道菌群失调的目前尚不明确，可能的原因包括有：</p><sec id="s7_4_1"><title>3.4.1. 膳食</title><p>CKD患者因为要控制钾离子的摄入，不能食用过多的新鲜水果和蔬菜，必将导致果糖和纤维素量的减少，以及与蛋白质的比例失调，肠道菌群中肠杆菌属细菌量将增加 [<xref ref-type="bibr" rid="hanspub.40027-ref16">16</xref>]。</p></sec><sec id="s7_4_2"><title>3.4.2. 结肠炎症</title><p>CKD患者一般都有体液和尿素的滞留，含氮物质在肠腔内长时间留存，引起结肠炎，从而导致肠道菌群发生改变 [<xref ref-type="bibr" rid="hanspub.40027-ref17">17</xref>]。</p></sec><sec id="s7_4_3"><title>3.4.3. 药物影响</title><p>CKD患者长期服用磷酸盐结合剂、铁剂，以及治疗过程中使用的抗生素等药物都会对肠道菌群产生影响 [<xref ref-type="bibr" rid="hanspub.40027-ref18">18</xref>]。CKD患者肠道菌群失调可引起局部或者全身性的炎症反应、尿毒症毒素的增加，从而将加快 CKD 进展 [<xref ref-type="bibr" rid="hanspub.40027-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.40027-ref19">19</xref>]。</p></sec></sec></sec><sec id="s8"><title>4. 研究与展望</title><p>肠道菌群十分庞大，组成及结构复杂，且不同人群中肠道菌群的组成和菌株种类存在差异，肠道菌群失调与CKD的发生关系密切相关，但如何能有效地调控肠道菌群，减少或延缓疾病的发生，特别是减少CKD的产生，仍需进行大量的研究。随着人类微生物组研究和高通量基因组测序技术的应用，我们对肠道菌群的研究将越来越深入，进而为以肠道菌群为靶点的预防和治疗相关疾病提供强有力的理论基础。</p></sec><sec id="s9"><title>基金项目</title><p>本文由广西重点实验室建设项目(20-065-76)；桂林市研究与技术开发计划项目(20170117-1)提供资助。</p></sec><sec id="s10"><title>文章引用</title><p>薛 雯,唐立红,朱俊芳,陈洁晶,刘永玲. 肠道菌群与慢性肾脏病的研究进展Research Progress of Intestinal Flora and Chronic Kidney Disease[J]. 临床医学进展, 2021, 11(01): 345-349. https://doi.org/10.12677/ACM.2021.111049</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40027-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sender, R., Fuchs, S. and Milo, R. (2016) Are We Really Vastly Outnumbered Revisiting the Ratio of Bacterial to Host Cells in Humans. Cell, 164, 337-340. https://doi.org/10.1016/j.cell.2016.01.013</mixed-citation></ref><ref id="hanspub.40027-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">翟齐啸, 田丰伟, 王刚, 陈卫. 肠道微生物与人体健康的研究进展[J]. 食品科学, 2013, 34(15): 337.</mixed-citation></ref><ref id="hanspub.40027-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">龙晓蕾, 李梓民, 周月婵, 等. 低聚果糖口服液对人体肠道菌群的影响[J]. 应用预防医学, 2016, 22(3): 227-229.</mixed-citation></ref><ref id="hanspub.40027-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ranganat Han, N., Ranganat Han, P., Friedman, E.A., et al. (2010) Pilot Study of Probiotic Dietary Supplementation for Promoting Healthy Kidney Function in Patients with Chronic Kidney Disease. Advances in Therapy, 27, 634-647.  
https://doi.org/10.1007/s12325-010-0059-9</mixed-citation></ref><ref id="hanspub.40027-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Andrade-Oliveira, V., Amano, M.T., Correacosta, M., et al. (2015) Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. Journal of the American Society of Nephrology, 26, 1877-1888.  
https://doi.org/10.1681/ASN.2014030288</mixed-citation></ref><ref id="hanspub.40027-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">中华人民共和国国家卫生和计划生育委员会. WS/T 557-2017慢性肾脏病患者膳食指导[Z]. 2017-08-01.</mixed-citation></ref><ref id="hanspub.40027-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Jha, V., Garcia, G., Iseki, K., et al. (2013) Chronic Kidney Disease: Global Dimension and Perspectives. The Lancet, 382, 260-272. https://doi.org/10.1016/S0140-6736(13)60687-X</mixed-citation></ref><ref id="hanspub.40027-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王尊松, 崔美玉, 唐利军, 等. 尿毒症患者肠道菌群变化的研究[J]. 中华肾脏病杂志, 2014, 30(3): 172-176.</mixed-citation></ref><ref id="hanspub.40027-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Martins, F.S., Silva, A.A., Vieira, A.T., et al. (2009) Comparative Study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii Probiotic Properties. Archives of Microbiology, 191, 623-630.  
https://doi.org/10.1007/s00203-009-0491-x</mixed-citation></ref><ref id="hanspub.40027-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Goto, S., Yoshiya, K., Kita, T., et al. (2011) Uremic Toxins and Oral Adsorbents. Therapeutic Apheresis and Dialysis, 15, 132-134. https://doi.org/10.1111/j.1744-9987.2010.00891.x</mixed-citation></ref><ref id="hanspub.40027-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kotanko, P., Carter, M. and Levin, N.W. (2006) Intestinal Bacterial Microflora a Potential Source of Chronic Inflammation in Patients with Chronic Kidney Disease. Nephrology Dialysis Transplantation, 21, 2057-2060.  
https://doi.org/10.1093/ndt/gfl281</mixed-citation></ref><ref id="hanspub.40027-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lin, C.J., Liu, H.L., Pan, C.F., et al. (2012) Indoxyl Sulfate Predicts Cardio Vascular Disease and Renal Function Deterioration in Advanced Chronic Kidney Disease. Archives of Medical Research, 43, 451-456.  
https://doi.org/10.1016/j.arcmed.2012.08.002</mixed-citation></ref><ref id="hanspub.40027-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Shimizu, H., Bolali, D., Adiang, A., et al. (2011) NF-κB Plays an Important Role in Indoxyl Sulfate-Induced Cellular Senescence, Fibrotic Gene Expression, and Inhibition of Proliferation in Proximal Tubular Cells. American Journal of Physiology-Cell Physiology, 301, c1201-c1212. https://doi.org/10.1152/ajpcell.00471.2010</mixed-citation></ref><ref id="hanspub.40027-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Niwa, T. (2010) Indoxyl Sulfate Is a Nephm-Vascular Toxin. Journal of Renal Nutrition, 20, S2-S6.  
https://doi.org/10.1053/j.jrn.2010.05.002</mixed-citation></ref><ref id="hanspub.40027-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Niwa, T. and Shimizu, H. (2012) Indoxyl Sulfate Induces Nephrovascular Senescence. Journal of Renal Nutrition, 22, 102-106. https://doi.org/10.1053/j.jrn.2011.10.032</mixed-citation></ref><ref id="hanspub.40027-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sabatino, A., Regolisti, G., Brusasco, I., et al. (2015) Alterations of Intestinal Barrier and Microbiota in Chronic Kidney Disease. Nephrology Dialysis Transplantation, 30, 924-933. https://doi.org/10.1093/ndt/gfu287</mixed-citation></ref><ref id="hanspub.40027-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">张镭, 聂静. 肠道菌群与慢性肾脏病[J]. 临床肾脏病杂志, 2016, 16(11): 697-700.</mixed-citation></ref><ref id="hanspub.40027-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Vaziri, N.D., Wong, J., Pahl, M., et al. (2013) Chronic Kidney Disease Alters Intestinal Microbial Flora. Kidney International, 83, 308-315. https://doi.org/10.1038/ki.2012.345</mixed-citation></ref><ref id="hanspub.40027-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Nallu, A., Sharma, S., Ramezani, A., et al. (2017) Gut Microbiome in Chronic Kidney Disease: Challenges and Opportunities. Translational Research, 179, 24-37. https://doi.org/10.1016/j.trsl.2016.04.007</mixed-citation></ref></ref-list></back></article>